Changchun, China – August 28, 2025, MGI Tech Co., Ltd. and JCBio Co., Ltd. have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, marking a significant collaboration to accelerate multi-omics research and precision medicine in South Korea.
Partnership Overview
The collaboration combines MGI’s advanced omics technologies with JCBio’s local expertise to strengthen South Korea’s position as a regional leader in genomics and biotechnology. The partnership will focus on multi-omics research advancement, novel sequencing applications, precision medicine development, clinical translation, and AI-driven data insights.
The DCS Lab Project
Under this initiative, JCBio will implement cutting-edge sequencing strategies using MGI’s proprietary short-read and long-read sequencing technologies. The laboratory will serve as a local hub for genomic research, equipped with end-to-end multi-omics capabilities that enable researchers to address complex biological challenges with enhanced precision and efficiency. Key capabilities include integrated multi-omics analyses, innovative sequencing strategies, accelerated precision medicine research, advanced clinical translation, and AI-powered data insights.
About the DCS Lab Initiative
Launched in 2023, MGI’s DCS Lab Initiative represents the company’s first global program targeting international laboratories with a focus on frontier science. The initiative is named after MGI’s three core technologies: DNA genomics, cell omics, and spatial omics. The program has already demonstrated success at MGI’s Customer Experience Centre (CEC) in Australia, where technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer research, medicine, and agriculture.
Executive Commentary
Dr. Roy Tan, Director of MGI Northeast Asia: “We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation. With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea’s research community with the tools to drive frontier science and improve human health.”
JaeChan Yoo, CEO of JCBio: “This partnership with MGI is a game-changer for South Korea’s research community. By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea’s growing role in global genomics research.”
About JCBio
JCBio Co., Ltd., founded in 2005, is a leading South Korean biotechnology company that serves as a key provider of research and diagnostic products in the country’s life sciences sector. The company’s mission focuses on enhancing longevity and improving quality of life.
